StreetInsider.com News Articles

Form 4 Century Therapeutics, For: Aug 14 Filed by: Pfeiffenberger Brent

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944526.html

Form 4 Century Therapeutics, For: Aug 14 Filed by: Pfeiffenberger Brent

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944526.html

Form 8-K Century Therapeutics, For: Aug 12

Wed, 12 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26909327.html

Form 8-K Century Therapeutics, For: Aug 12

Wed, 12 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26909327.html

Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 6c

Wed, 12 Aug 2026 08:03:57 -0400

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

Form 10-Q Century Therapeutics, For: Jun 30

Wed, 12 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26909239.html

Form 10-Q Century Therapeutics, For: Jun 30

Wed, 12 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26909239.html

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Wed, 12 Aug 2026 08:00:00 -0400

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026
CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D
Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D^® Clinical & Research Congress 2026 highlighting CNTY-813
Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion^™ 5.0 into the

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Wed, 12 Aug 2026 08:00:00 -0400

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026
CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D
Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D^® Clinical & Research Congress 2026 highlighting CNTY-813
Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion^™ 5.0 into the

Form 4 Century Therapeutics, For: Aug 03 Filed by: Carr Douglas

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874185.html

Form 4 Century Therapeutics, For: Aug 03 Filed by: Carr Douglas

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874185.html

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific conferences scheduled for fall 2026, according to a company statement.

The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present in a session focused on stem cell-to-beta cell therapy.

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:26 -0400

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia,

Century Therapeutics to present CNTY-813 preclinical data at two fall congresses

Thu, 09 Jul 2026 08:00:18 -0400

Century Therapeutics (NASDAQ: IPSC) announced that preclinical data for its CNTY-813 program have been accepted for oral presentations at two scientific meetings scheduled for fall 2026, according to a company press release.

The first presentation is scheduled for October 2, 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Grant Welstead, PhD, Senior Vice President and Head of Research at Century Therapeutics, will present during a session focused on stem cell-to-beta cell therapy.

The second presentation is set for October 9, 2026, at the Breakthrough T1D Clinical & Research Congress 2026 in

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026